Asia
It was another busy week in clinical trial news. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Junshi Biosciences announced that the Phase III clinical trial it is conducting alongside Coherus BioSciences on a potential non-small cell lung cancer drug shows positive preliminary results.
Global biopharma and life sciences companies provide updates to their businesses and pipelines.
In the past few weeks, China reminded the world that it is, first and foremost, a Communist nation. The recent crackdowns on the high-tech and education industries make some wonder what other changes will be next.
In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceuticals won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines.
An interim analysis of a Phase III study shows that a combination of Innovent’s sintilimab with chemotherapy significantly improves overall survival compared with placebo in the first-line management of patients with advanced gastric cancer.
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. FDA, which will speed up the regulatory process for these medications.
There was plenty of clinical trial updates last week. Here’s a look.
PRESS RELEASES